Mental ill-health in MS: prevalence and causes
February 2026 – by Prof. Gavin Giovannoni It is now well established that the burden of MS extends far beyond…
Categories
Latest Blog Posts
- Talking Biosimilars – Unlocking Patient access through coordinated action
- Beyond One Drug: What the Tolebrutinib Decision Teaches Us About Progressive MS Trials.
- MS Trial Alert: Investigators Recruiting Nationwide for Study Comparing AHSCT to Other Therapies in Active Relapsing MS
- Genentech’s Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)
- Eating well with MS can be an effective in managing symptoms
- Pseudobulbar affect in MS
- Catch-up on Our Mental Wellness Chat Series
- High-dose vitamin D can help delay progression to MS
- Having parents who smoked increases risk of pediatric MS: Study
- MRI and MS diagnosis
- Ocrevus and Tysabri appear to work equally well to control relapsing MS
- Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial
- Japanese researchers build robotic tail to keep elderly upright
- Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs
- Scientists find the Brain’s “Reset Switch” that breaks life into separate memories
- Welcome to The Brain Health Minute, where science meets action, one minute at a time.
- Predictors of initiating high-efficacy vs. platform therapies as first-line disease-modifying treatment in multiple sclerosis
- Expert Panel Publishes Revised Consensus Recommendations for Diagnosis and Management of NMOSD
- REFRAMING MS
- Natalizumab-sztn is an FDA-approved monotherapy for all indications of the reference product natalizumab, including relapsing forms of multiple sclerosis and Crohn disease.
